HAYWARD, Calif., Sept. 6, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that Chief Executive Officer,
Vince Angotti will present in-person
and be available for one-on-one meetings throughout the H.C.
Wainwright Annual Investment Conference, to be held in person and
virtually September 12-14, 2022 in
New York, NY.
H.C. Wainwright Annual Investment Conference
Format:
Live presentation and 1x1 Meetings
Date: Monday, September
12th, 2022
Time: 12:00 PM EDT
Webcast Link: [CLICK HERE]
The recorded presentation will also be available for 90 days on
AcelRx's website within the Investors/News/Events section.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals,
Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's proprietary, non-invasive sublingual formulation
technology delivers sufentanil with consistent pharmacokinetic
profiles. The Company has one approved product in the U.S.,
DSUVIA® (sufentanil sublingual tablet, 30 mcg), approved as DZUVEO®
in Europe, indicated for the management of acute pain severe
enough to require an opioid analgesic for adult patients in
certified medically supervised healthcare settings, and several
product candidates. The Company's product candidates include: two
developmental pre-filled, ready-to-use syringes of ephedrine and
phenylephrine licensed for the U.S. from Aguettant;
Niyad™, a developmental device for use as a regional anticoagulant
for the extracorporeal circuit; LTX-608, for the potential
treatment of COVID-19, disseminated intravascular coagulation,
acute respiratory distress syndrome and acute pancreatitis; and
Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg),
an investigational product in the U.S. being developed as
an innovatively designed patient-controlled analgesia (PCA) system
for reduction of moderate-to-severe acute pain in medically
supervised settings.
This release is intended for investors only. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-in-the-hc-wainwright-annual-investment-conference-301618628.html
SOURCE AcelRx Pharmaceuticals, Inc.